In Brief: IDEC Pharmaceuticals/Seikagaku
IDEC Pharmaceuticals/Seikagaku: Enter PRIMATIZED antibody collaboration for development of CD23 antigen antibody for allergic rhinitis, asthma and other allergic conditions, IDEC announces Feb. 2. The Japanese glycoscience corporation "may provide up to $26 mil. in license fee payments and support for research and development at IDEC, dependent on reaching specific development milestones." The two companies will share product rights derived from the collaboration; IDEC will receive royalties on eventual product sales. IDEC says that antibodies against the CD23 receptor on certain white blood cells have been found to inhibit the production of immunoglobulin class E molecules, known to cause allergic conditions...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth